The Middle East & Africa active pharmaceutical ingredient market is projected to boom in the upcoming five years while exhibiting an impressive CAGR. In the last five years, from 2017 to 2021, the market has experienced quite a growth that was counted in millions of sales. It is anticipated to project its growth in the forecast period, 2023-2027, on account of a surge in demand for effective and efficient pharmaceutical products. The increasing instances of chronic diseases and complex treatment strategies are demanding the presence of active pharmaceutical ingredients, and the factor is actively driving the growth of the Middle East & Africa active pharmaceutical ingredient market in the upcoming five years.
Moreover, advancing government initiatives and regulations for the active pharmaceutical ingredient production, along with the changes in the geopolitical changes, are supporting the growth of the Middle East & Africa active pharmaceutical ingredient market in the next five years. Additionally, with rapidly increasing research and development in the active pharmaceutical ingredient to enhance the quality and efficiency of the drugs they are part of, the market is anticipated to show robust growth in the future five years of forecast. Furthermore, the rapidly increasing number of market players in the region is responsible for the substantial future growth of the Middle East & Africa active pharmaceutical ingredient market in the forecast period until 2027.
Any substance or combination of substances used in a finished pharmaceutical product (FPP), intended to furnish pharmacological activity or to otherwise have direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to have direct effect in restoring, correcting or modifying physiological functions in human beings is the textbook definition of active pharmaceutical ingredient (API).
The Middle East & Africa active pharmaceutical ingredient market is segmented by the method of synthesis, source, therapeutic application, molecule type, potency, drug type, competitional landscape, and country distribution. Based on the source, the market is divided between contact manufacturing organizations and in-house manufacturing. In-house manufacturing is anticipated to hold the larger revenue shares of the market and assert its dominance over the market on account of easier availability of raw material in the manufacturing units as well as their compatibility with the drug production. Market players have actively taken initiatives for in-house manufacturing and thereby supporting the growth of the market in the next five years. Although contact manufacturing is expected to register the fastest growing CAGR in the upcoming years since the countries like UAE, South Africa are actively involved in the contract-based production of API.
Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., Neopharma LLC, CAD Middle East Pharmaceutical Industries LLC, KMK Chemicals FZ LLC, Approcare Middle East, AstraZeneca Plc., AbbVie Inc., Ketlaphela Pharmaceutical SOC Ltd, Afriplex (Pty) Ltd, Temad Co., Sanofi S.A., among others form a partial list of leading market players. These companies are actively involved with the research and development process of the active pharmaceutical ingredients in the region. Countries like Saudi Arabia, UAE, South Africa, have dedicated research labs for advanced products development and consistent product modifications. The recent trend of efficient and effective pharmaceutical demands has enticed the market players to explore the area and come up with advanced products that would satisfy the emerging consumer demands.
Objective of the Study
- To analyze and forecast the market size of Middle East & Africa active pharmaceutical ingredient market from 2017 to 2020.
- To estimate and forecast the market size of Middle East & Africa active pharmaceutical ingredient market from 2021 to 2027 and growth rate until 2027.
- To classify and forecast Middle East & Africa active pharmaceutical ingredient market based on method of synthesis, source, therapeutic application, molecule type, potency, drug type, competitional landscape, and country distributions.
- To identify dominant region or segment in the Middle East & Africa active pharmaceutical ingredient market.
- To identify drivers and challenges for Middle East & Africa active pharmaceutical ingredient market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Middle East & Africa active pharmaceutical ingredient market.
- To identify and analyze the profile of leading players operating in Middle East & Africa active pharmaceutical ingredient market.
- To identify key sustainable strategies adopted by market players in Middle East & Africa active pharmaceutical ingredient market.
Click here to download the sample
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of
Key Target Audience
- Manufacturers, end users, and other stakeholders
- Distributers and suppliers and other stakeholders
- Organizations, forums, and alliances related to active pharmaceutical ingredients.
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
| Attribute | Details |
| Base Year | 2021 |
| Historic Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Method of Synthesis · Source · Therapeutic Application · Molecule Type · Potency · Drug Type |
| Country scope | Saudi Arabia; UAE; Israel; Bahrain; South Africa; Nigeria; Egypt; Algeria; Morocco |
| Key companies profiled | Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Cipla Inc., Neopharma LLC, CAD Middle East Pharmaceutical Industries LLC, KMK Chemicals FZ LLC, Approcare Middle East, AstraZeneca Plc., AbbVie Inc., Ketlaphela Pharmaceutical SOC Ltd, Afriplex (Pty) Ltd, Temad Co., Sanofi S.A. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
